Mahableshwar Shankar Albur

Dr. Mahableshwar Shankar Albur

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2019 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
RBRoss J. Burton
Ross J. Burton
MAMahableshwar Shankar Albur
Mahableshwar Shankar Albur
MEMatthias Eberl
Matthias Eberl
SCSimone Cuff
Simone Cuff
A substantial proportion of microbiological screening in diagnostic laboratories is due to suspected urinary tract infections (UTIs), yet approximately two thirds of urine samples typically yield negative culture results. By reducing the number of query samples to be cultured and enabling diagnostic services to concentrate on those in which there are true microbial infections, a significant improvement in efficiency of the service is possible. Screening process for urine samples prior to culture was modelled in a single clinical microbiology laboratory covering three hospitals and community services across Bristol and Bath, UK. Retrospective analysis of all urine microscopy, culture, and sensitivity reports over one year was used to compare two methods of classification: a heuristic model using a combination of white blood cell count and bacterial count, and a machine learning approach testing three algorithms (Random Forest, Neural Network, Extreme Gradient Boosting) whilst factoring in independent variables including demographics, historical urine culture results, and clinical details provided with the specimen. A total of 212,554 urine reports were analysed. Initial findings demonstrated the potential for using machine learning algorithms, which outperformed the heuristic model in terms of relative workload reduction achieved at a classification sensitivity > 95%. Upon further analysis of classification sensitivity of subpopulations, we concluded that samples from pregnant patients and children (age 11 or younger) require independent evaluation. First the removal of pregnant patients and children from the classification process was investigated but this diminished the workload reduction achieved. The optimal solution was found to be three Extreme Gradient Boosting algorithms, trained independently for the classification of pregnant patients, children, and then all other patients. When combined, this system granted a relative workload reduction of 41% and a sensitivity of 95% for each of the stratified patient groups. Based on the considerable time and cost savings achieved, without compromising the diagnostic performance, the heuristic model was successfully implemented in routine clinical practice in the diagnostic laboratory at Severn Pathology, Bristol. Our work shows the potential application of supervised machine learning models in improving service efficiency at a time when demand often surpasses resources of public healthcare providers.

17 December 2020 in eLife
Verified
Journal Article
Open access
MGMichaela Gregorova
Michaela Gregorova
DMDaniel Morse
Daniel Morse
TBTarcisio Brignoli
Tarcisio Brignoli
JSJoseph Steventon
Joseph Steventon
FHFergus Hamilton
Fergus Hamilton
RMRuth C Massey
Ruth C Massey
Here, we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas aeruginosa that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis revealed the AMR genotype, while immunological analysis revealed massive and escalating levels of T-cell activation. These were both SARS-CoV-2 and P. aeruginosa specific, and bystander activated, which may have contributed to this patient’s persistent symptoms and radiological changes.

1 May 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
NPNeil Powell
Neil Powell
PHPhilip Howard
Philip Howard
MLMartin J. Llewelyn
Martin J. Llewelyn
Tamas SzakmanyTamas Szakmany
Tamas Szakmany
MAMahableshwar Shankar Albur
Mahableshwar Shankar Albur
JSJonathan Sandoe
Jonathan Sandoe
A minority of patients presenting to hospital with COVID-19 have bacterial co-infection. Procalcitonin testing may help identify patients for whom antibiotics should be prescribed or withheld. This study describes the use of procalcitonin in English and Welsh hospitals during the first wave of the COVID-19 pandemic. A web-based survey of antimicrobial leads gathered data about the use of procalcitonin testing. Responses were received from 148/151 (98%) eligible hospitals. During the first wave of the COVID-19 pandemic, there was widespread introduction and expansion of PCT use in NHS hospitals. The number of hospitals using PCT in emergency/acute admissions rose from 17 (11%) to 74/146 (50.7%) and use in Intensive Care Units (ICU) increased from 70 (47.6%) to 124/147 (84.4%). This increase happened predominantly in March and April 2020, preceding NICE guidance. Approximately half of hospitals used PCT as a single test to guide decisions to discontinue antibiotics and half used repeated measurements. There was marked variation in the thresholds used for empiric antibiotic cessation and guidance about interpretation of values. Procalcitonin testing has been widely adopted in the NHS during the COVID-19 pandemic in an unevidenced, heterogeneous way and in conflict with relevant NICE guidance. Further research is needed urgently that assesses the impact of this change on antibiotic prescribing and patient safety.

28 November 2022 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
JEJoanne Euden
Joanne Euden
PPPhilip Pallmann
Philip Pallmann
DGDetelina Grozeva
Detelina Grozeva
MAMahableshwar Shankar Albur
Mahableshwar Shankar Albur
SBStuart Bond
Stuart Bond
JSJonathan Sandoe
Jonathan Sandoe
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience secondary bacterial infections, and the assumption that they may respond well to antibiotic therapy. This has led to an increase in antibiotic use for some hospitalised patients at a time when accumulating antibiotic resistance is a major global threat to health. Procalcitonin (PCT) is an inflammatory marker measured in blood samples and widely recommended to help diagnose bacterial infections and guide antibiotic treatment. The PEACH study will compare patient outcomes from English and Welsh hospitals that used PCT testing during the first wave of the COVID-19 pandemic with those from hospitals not using PCT. It will help to determine whether, and how, PCT testing should be used in the NHS in future waves of COVID-19 to protect patients from antibiotic overuse. PEACH is a retrospective observational cohort study using patient-level clinical data from acute hospital Trusts and Health Boards in England and Wales. The primary objective is to measure the difference in antibiotic use between COVID-19 patients who did or did not have PCT testing at the time of diagnosis. Secondary objectives include measuring differences in length of stay, mortality, intensive care unit admission, and resistant bacterial infections between these groups.

18 August 2021 in BJGP Open
Verified
Journal Article
Open access
PDF file
TSToby Peter Speirs
Toby Peter Speirs
NTNicole Tuffin
Nicole Tuffin
FMFinlay Mundy-Baird
Finlay Mundy-Baird
HSHelena Sakota
Helena Sakota
SMSarah Mulholland
Sarah Mulholland
Huzaifa AdamaliHuzaifa Adamali
Huzaifa Adamali
Background: Long-term nitrofurantoin (NF) treatment can result in pulmonary and hepatic injury. Current guidelines do not outline the type or frequency of monitoring required for detection of these injuries.Aim: To assess 1) awareness of NF complications among prescribers; 2) monitoring practice; and 3) to describe the pulmonary sequelae of NF-related complications.Design & setting: Evaluation of prescribing habits by questionnaires and review of GP databases, and case-note review in secondary care.Method: The following study procedures were undertaken: 1) an electronic questionnaire was distributed to prescribers, interrogating prescribing and monitoring practices, and awareness of complications; 2) an analysis was undertaken (June–July 2020) of NF monitoring among GPs in the local clinical commissioning group (CCG); and 3) a case review was carried out of patients diagnosed with NF-induced interstitial lung disease (NFILD) at the interstitial lung disease (ILD) centre (2014–2020).Results: A total of 125 prescribers of long-term NF responded to the questionnaire (82.4% GPs; 12.0% urologists). Many were unaware of the potential for liver (42.4%) and lung (28.0%) complications; 40.8% and 52.8% never monitored for these, respectively. Only 53.3% of urologists believed themselves responsible for arranging monitoring, while nearly all GPs believed this to be the prescriber’s responsibility (94.2%). One-third of all responders considered current British National Formulary (BNF) guidelines 'not at all sufficient/clear', with mean clarity scoring of 2.2/5. Among patients with NFILD (n = 46), NF had been prescribed most often (69.6%) for treatment of recurrent UTI and 58.6% (n = 27) were prescribed for >6 months. On withdrawal of the medication 61.4% displayed resolution (completely or minimal fibrosis), while 15.9% of patients had progressive lung fibrosis.Conclusion: NF can cause marked or irreversible lung complications and there is currently a shortfall in awareness and monitoring. Existing monitoring guidelines should be augmented.

10 March 2025 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
BSBrian Sullivan
Brian Sullivan
EBEdward Barker
Edward Barker
LMLouis MacGregor
Louis MacGregor
LGLeo Gorman
Leo Gorman
PWPhilip Williams
Philip Williams
MAMahableshwar Shankar Albur
Mahableshwar Shankar Albur
Purpose: Assessing risk factors and creating prediction models from real-world medical data is challenging, requiring numerous modelling decisions with clinical guidance. Logistic regression is a common model for such studies, for which we advocate the use of Bayesian methods that can jointly deliver probabilistic risk factor inference and prediction. As an exemplar, we compare Bayesian logistic regression with horseshoe priors and Projective Prediction variable selection with the established frequentist LASSO approach, to predict severe COVID-19 outcomes (death or ICU admittance) from demographic and laboratory biomarker data. Our study serves as guidance on data curation, variable selection, and performance assessment with cross-validation. Methods: Our source data is based on a retrospective observational cohort design with records from three National Health Service (NHS) Trusts in southwest England, UK. Models were fit to predict severe outcomes within 28 days after admission to hospital (or a positive PCR result if already admitted) using demographic data and the first result from 30 biomarker tests collected within 3 days after admission (or testing positive if already admitted). Results: Patients included hospitalized adults positive for COVID-19 from March to October 2020, 756 total patients: Mean age 71, 45% female, 31% (n=234) had a severe outcome, of whom 88% (n=206) died. Patients were split into training (n=534) and external validation groups (n=222). Using our Bayesian pipeline, we show a reduced variable model using Age, Urea, Prothrombin time (PT) C-reactive protein (CRP), and Neutrophil-Lymphocyte ratio (NLR) has better predictive performance (median external AUC: 0.71, 95% Quantile [0.7, 0.72]) relative to a GLM using all variables (external AUC: 0.67 [0.63, 0.71]). Conclusion: Urea, PT, CRP, and NLR have been highlighted by other studies, and respectively suggest that hypovolemia, derangement of circulation via clotting, and inflammation are strong predictive risk factors of severity. This study provides guidance on conventional and Bayesian regression and prediction modelling with complex clinical data.